News ImmuneRegen NewsImmuneRegen BioSciences Begins FDA Requested Radiation StudySCOTTSDALE, Ariz., June 16 /PRNewswire/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBO) will award a grant to the University of Arizona College of Medicine to begin an experimental study to test whether Homspera™ has efficacy as a treatment for gamma radiation by direct muscle injection at the same success level as by aerosol administration. The study will be directed by Dr. Mark Witten and will begin on June 28th 2004. Homspera™ as it pertains to radiation, has demonstrated a survival rate of 50% as well as other potential benefits during previous radiation studies. ImmuneRegen maintains that Homspera™ can potentially be utilized as a countermeasure against lethal gamma radiation exposure. This study was requested by the U.S. Food & Drug Administration (FDA) in a meeting with ImmuneRegen Biosciences, Inc. executives and scientists earlier this spring. The U.S. Food & Drug Administration (FDA) is interested in potentially utilizing Homspera™ as a countermeasure against acute radiation exposure by either military personnel or emergency first responders. "Getting a request from the FDA for further radiation studies is especially encouraging for us," said ImmuneRegen's CEO Michael Wilhelm. "It's an indication that we are being seriously considered by the federal government as a resource in protecting the homeland. We look forward to playing a vital role in such a solemn responsibility." About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|